NCT04265092View on ClinicalTrials.gov

Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

January 31, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Incobotulinum toxin A

Treatment consisted of 200 IU of incobotulinum toxinA injected into the TS. Outcome measures were assessed before injection, at 6 weeks and 3 months post-injection, using the Goal Attainment Scale (GAS), Twelve Item MS Walking (MSWS-12) Scale, Timed Up and Go (TUG) Test, 6 Minute Walk Test (6MWT). Spatiotemporal gait data was obtained by GAITRite.

All Listed Sponsors
lead

Pôle Saint Hélier

OTHER

NCT04265092 - Therapeutic Benefit of Incobotulinum Toxin A for Spasticity of the Triceps Surae in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter